Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024

In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.

Citation:
Drislane S, Moore H, Attwell K. Understanding parental decisions to decline or delay infant RSV immunisation, nirsevimab, in Western Australia in 2024. Vaccine. 2026;72.

Keywords:
Delayed immunisation; Hesitancy; Nirsevimab; Parent attitudes; Personal risk assessment; RSV immunisation

Abstract:
In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.